EVALUATION OF RETINAL TOXICITY AND EFFICACY OF THE ANTICYTOMEGALOVIRUS COMPOUND 2-AMINO-7-[(1,3-DIHYDROXY-2-PROPOXY)METHYL]PURINE

被引:4
作者
BESEN, G
CHAVEZDELAPAZ, E
TATEBAYASHI, M
FLORESAGUILAR, M
GANGAN, PA
MUNGUIA, D
WILEY, CA
JAHNE, G
WINKLER, I
HELSBERG, M
BERGERONLYNN, G
FREEMAN, WR
机构
[1] UNIV CALIF SAN DIEGO,SHILEY EYE CTR,SCH MED,DEPT OPHTHALMOL,LA JOLLA,CA 92093
[2] UNIV PITTSBURGH,SCH MED,DEPT PATHOL,PITTSBURGH,PA
[3] HOECHST AG,SBU ANTIINFEKT RES,FRANKFURT,GERMANY
关键词
D O I
10.1128/AAC.39.7.1485
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Compound 2242, also known as 2-amino-7-[(1,3-dihydroxy-2-propoxy)methyl]purine, is the first known antivirally active nucleoside analog with the side chain substituted at the N-7 position of the purine ring system. Our purpose was to evaluate its retinal toxicity and assess the efficacy of its highest nontoxic concentration in a rabbit model of herpes simplex retinitis. Concentrations of the drug from 0.5 to 2,000 mu M were injected intravitreally in twelve New Zealand White rabbits. Fundoscopic, histologic, and electrophysiologic data revealed no evidence of toxicity even at the highest dose of the compound. Dutch pigmented rabbits (n = 34) had their left eyes injected with herpes simplex virus type 1 3 days after, concurrently, or 3 days before intravitreal injection of either 2,000 mu M compound 2242 or 480 mu M ganciclovir (final concentration in the eye). Both compound 2242 and ganciclovir were equally effective compared with saline when administered simultaneously with the virus (P < 0.0001). In the 3-day pretreatment paradigm, compound 2242 was superior to ganciclovir (P < 0.04), but there was no clear difference between the two with regard to their effects on an established infection. The pharmacokinetics of compound 2242 in 10 rabbits injected intravitreally with 30 mu M showed an intravitreal half-life of 8 h. This compound, which may be orally active in its pro form, has a very high therapeutic index in the eye and is more efficient than ganciclovir in this animal model of herpes retinitis.
引用
收藏
页码:1485 / 1488
页数:4
相关论文
共 33 条
[1]   CONTROL OF CYTOMEGALOVIRUS RETINITIS USING SUSTAINED-RELEASE OF INTRAOCULAR GANCICLOVIR [J].
ANAND, R ;
NIGHTINGALE, SD ;
FISH, RH ;
SMITH, TJ ;
ASHTON, P .
ARCHIVES OF OPHTHALMOLOGY, 1993, 111 (02) :223-227
[2]   TREATMENT OF CYTOMEGALO-VIRUS RETINITIS WITH INTRAVITREAL GANCICLOVIR - LONG-TERM RESULTS [J].
CANTRILL, HL ;
HENRY, K ;
MELROE, NH ;
KNOBLOCH, WH ;
RAMSAY, RC ;
BALFOUR, HH .
OPHTHALMOLOGY, 1989, 96 (03) :367-374
[3]   CHEMISTRY AND ANTIVIRAL ACTIVITIES OF ACYCLONUCLEOSIDES [J].
CHU, CK ;
CUTLER, SJ .
JOURNAL OF HETEROCYCLIC CHEMISTRY, 1986, 23 (02) :289-319
[4]  
COCHEREAUMASSIN I, 1991, OPHTHALMOLOGY, V98, P1348
[5]   INTRAVITREAL FOSCARNET FOR CYTOMEGALOVIRUS RETINITIS IN A PATIENT WITH ACQUIRED-IMMUNODEFICIENCY-SYNDROME [J].
DIAZLLOPIS, M ;
CHIPONT, E ;
SANCHEZ, S ;
ESPANA, E ;
NAVEA, A ;
MENEZO, JL .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1992, 114 (06) :742-747
[6]  
DOLNAK DR, 1992, INVEST OPHTH VIS SCI, V33, P1557
[7]   PROGRESSIVE DISEASE DUE TO GANCICLOVIR-RESISTANT CYTOMEGALO-VIRUS IN IMMUNOCOMPROMISED PATIENTS [J].
ERICE, A ;
CHOU, S ;
BIRON, KK ;
STANAT, SC ;
BALFOUR, HH ;
JORDAN, MC .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 320 (05) :289-293
[8]  
FANNING MM, 1990, J ACQ IMMUN DEF SYND, V3, P472
[9]  
FLORESAGUILAR M, 1993, OPHTHALMOLOGY, V100, P1022
[10]  
FLORESAGUILAR M, 1994, RETINA, V15, P3